The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- With Mandatory CDISC-Based Submission Looming, CRO A2 Sees Soaring Orders from Japanese Drug Makers
December 16, 2014
- Sanofi Reiterates Alert on Proper Use of Jevtana; Five Deaths Reported Since Launch in September
December 15, 2014
- Sumitomo Dainippon Aims for NDA Filing for ADHD Treatment Dasotraline in FY2017 in US
December 15, 2014
- Kyowa Kirin Aims to Score Global Sales of 20 Billion Yen for Poteligeo in a Few Years: President Hanai
December 15, 2014
- Astellas Reduces Sales Offices from 159 to 109, Aims to Better Respond to Specific Needs in Each Region: President Hatanaka
December 12, 2014
- Hanshin Dispensing Holding Joins Forces with Convenience Store Lawson
December 12, 2014
- Brexpiprazole Improves Schizophrenia in PIII: Otsuka, Lundbeck
December 11, 2014
- Eisai’s Orexin Receptor Antagonist Improves Sleep Initiation, Maintenance in PII Study
December 11, 2014
- Blopress AG Will Lose Steam after Launch of Rival Generics, Sawai Pres. Predicts
December 11, 2014
- Ono, Kyowa Kirin, BMS to Conduct PI Study of Opdivo and Poteligeo as Combination Therapy in Patients with Solid Tumors
December 11, 2014
- Humanized Bispecific Antibody for Hemophilia A Effective in PI Study: Chugai
December 10, 2014
- Alfresa to Acquire More Shares of Pharmacy Chain Operator
December 10, 2014
- Ethical Drug Sales 1.1%, in October: Crecon Report
December 10, 2014
- Efficacy of Lenalidomide in Treatment-Naïve Patients with Multiple Myeloma Confirmed in Domestic PII Study: Celgene
December 10, 2014
- Takeda, Monash University of Australia to Collaborate in Gastroenterology Field
December 10, 2014
- Data Suggest Potential Feasibility of Ixazomib as Maintenance Therapy for Multiple Myeloma: Takeda
December 9, 2014
- Eisai’s Fycompa Cuts Tonic-Clonic Seizure Frequency by 76.5%
December 9, 2014
- Adcetris Significantly Extends PFS in Post-Transplant Hodgkin lymphoma Patients: Takeda
December 9, 2014
- Abilify Maintena Approved for Use in Acutely Relapsed Adults with Schizophrenia in the US: Otsuka, Lundbeck
December 9, 2014
- April-September Sales Drop 21.5% for Major Long-Listed Products
December 8, 2014
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…